nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—prostate cancer	0.331	1	CbGaD
Tasosartan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.103	0.207	CbGbCtD
Tasosartan—CYP3A4—Bicalutamide—prostate cancer	0.0539	0.109	CbGbCtD
Tasosartan—CYP3A4—Estramustine—prostate cancer	0.0501	0.101	CbGbCtD
Tasosartan—CYP3A4—Flutamide—prostate cancer	0.0446	0.09	CbGbCtD
Tasosartan—CYP3A4—Abiraterone—prostate cancer	0.0446	0.09	CbGbCtD
Tasosartan—CYP3A4—Cabazitaxel—prostate cancer	0.033	0.0666	CbGbCtD
Tasosartan—CYP3A4—Estrone—prostate cancer	0.0323	0.0651	CbGbCtD
Tasosartan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0288	0.058	CbGbCtD
Tasosartan—CYP3A4—Conjugated Estrogens—prostate cancer	0.0211	0.0426	CbGbCtD
Tasosartan—CYP3A4—Mitoxantrone—prostate cancer	0.0192	0.0387	CbGbCtD
Tasosartan—CYP3A4—Estradiol—prostate cancer	0.0185	0.0374	CbGbCtD
Tasosartan—CYP3A4—Prednisone—prostate cancer	0.0159	0.0321	CbGbCtD
Tasosartan—CYP3A4—Etoposide—prostate cancer	0.0121	0.0244	CbGbCtD
Tasosartan—CYP3A4—Docetaxel—prostate cancer	0.0111	0.0223	CbGbCtD
Tasosartan—AGTR2—renal system—prostate cancer	0.00894	0.406	CbGeAlD
Tasosartan—CYP3A4—Doxorubicin—prostate cancer	0.00825	0.0166	CbGbCtD
Tasosartan—Losartan—UGT2B17—prostate cancer	0.00433	0.73	CrCbGaD
Tasosartan—CYP3A4—urine—prostate cancer	0.003	0.136	CbGeAlD
Tasosartan—AGTR1—prostate gland—prostate cancer	0.00294	0.133	CbGeAlD
Tasosartan—AGTR1—epithelium—prostate cancer	0.00216	0.098	CbGeAlD
Tasosartan—AGTR1—renal system—prostate cancer	0.002	0.0909	CbGeAlD
Tasosartan—AGTR1—testis—prostate cancer	0.00129	0.0588	CbGeAlD
Tasosartan—AGTR1—lymph node—prostate cancer	0.000937	0.0426	CbGeAlD
Tasosartan—CYP3A4—renal system—prostate cancer	0.000735	0.0334	CbGeAlD
Tasosartan—Losartan—CYP3A5—prostate cancer	0.000432	0.0728	CrCbGaD
Tasosartan—Losartan—ACE—prostate cancer	0.000398	0.0671	CrCbGaD
Tasosartan—Losartan—CYP2C19—prostate cancer	0.000294	0.0496	CrCbGaD
Tasosartan—Irbesartan—CYP3A4—prostate cancer	0.00029	0.0489	CrCbGaD
Tasosartan—Losartan—CYP3A4—prostate cancer	0.000187	0.0315	CrCbGaD
Tasosartan—AGTR1—Signaling Pathways—HIST1H2BG—prostate cancer	4.7e-05	0.000324	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	4.66e-05	0.000321	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GRB7—prostate cancer	4.66e-05	0.000321	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDE4D—prostate cancer	4.66e-05	0.000321	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—JAK2—prostate cancer	4.62e-05	0.000319	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ITPR1—prostate cancer	4.56e-05	0.000314	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HIST1H4H—prostate cancer	4.54e-05	0.000313	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCL8—prostate cancer	4.53e-05	0.000313	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PIK3CA—prostate cancer	4.53e-05	0.000312	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	4.52e-05	0.000312	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MDM2—prostate cancer	4.51e-05	0.000311	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—NCOA2—prostate cancer	4.5e-05	0.00031	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ERBB2—prostate cancer	4.45e-05	0.000307	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNG5—prostate cancer	4.43e-05	0.000305	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIK3CB—prostate cancer	4.39e-05	0.000303	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCL8—prostate cancer	4.22e-05	0.000291	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	4.19e-05	0.000289	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	4.14e-05	0.000285	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDKN1B—prostate cancer	4.12e-05	0.000284	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKT1—prostate cancer	4.08e-05	0.000281	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CASP3—prostate cancer	4.04e-05	0.000278	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL2—prostate cancer	4.03e-05	0.000278	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—prostate cancer	4.01e-05	0.000277	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.98e-05	0.000274	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCND1—prostate cancer	3.93e-05	0.000271	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.92e-05	0.00027	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CTNNB1—prostate cancer	3.89e-05	0.000268	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTHLH—prostate cancer	3.86e-05	0.000266	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFBR1—prostate cancer	3.86e-05	0.000266	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.85e-05	0.000266	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP9—prostate cancer	3.82e-05	0.000263	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDKN1A—prostate cancer	3.8e-05	0.000262	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKR1C3—prostate cancer	3.8e-05	0.000262	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.79e-05	0.000262	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTEN—prostate cancer	3.79e-05	0.000262	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKACB—prostate cancer	3.78e-05	0.00026	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	3.74e-05	0.000258	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKT1—prostate cancer	3.7e-05	0.000255	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	3.69e-05	0.000254	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PPP3CA—prostate cancer	3.68e-05	0.000254	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—THBS1—prostate cancer	3.68e-05	0.000254	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ANXA1—prostate cancer	3.63e-05	0.00025	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EP300—prostate cancer	3.62e-05	0.00025	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—RXRA—prostate cancer	3.61e-05	0.000249	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKCZ—prostate cancer	3.56e-05	0.000246	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SRC—prostate cancer	3.52e-05	0.000243	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CG—prostate cancer	3.48e-05	0.00024	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—COMT—prostate cancer	3.48e-05	0.00024	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTP1—prostate cancer	3.46e-05	0.000239	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGFR4—prostate cancer	3.44e-05	0.000237	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PARP1—prostate cancer	3.44e-05	0.000237	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	3.43e-05	0.000236	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—prostate cancer	3.43e-05	0.000236	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	3.41e-05	0.000235	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CALCA—prostate cancer	3.4e-05	0.000234	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—STAT3—prostate cancer	3.39e-05	0.000234	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL12—prostate cancer	3.32e-05	0.000229	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTM1—prostate cancer	3.18e-05	0.000219	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CG—prostate cancer	3.16e-05	0.000218	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MYC—prostate cancer	3.15e-05	0.000217	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—prostate cancer	3.14e-05	0.000217	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	3.14e-05	0.000216	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CASP9—prostate cancer	3.12e-05	0.000215	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—prostate cancer	3.08e-05	0.000213	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CD—prostate cancer	3.06e-05	0.000211	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKCQ—prostate cancer	3.03e-05	0.000209	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NGFR—prostate cancer	3.03e-05	0.000209	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	3.01e-05	0.000208	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAP3K7—prostate cancer	2.99e-05	0.000206	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HAO1—prostate cancer	2.97e-05	0.000205	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.97e-05	0.000205	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KRAS—prostate cancer	2.91e-05	0.000201	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGF10—prostate cancer	2.88e-05	0.000198	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRB2—prostate cancer	2.85e-05	0.000196	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—JAK2—prostate cancer	2.81e-05	0.000194	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MAP2K1—prostate cancer	2.8e-05	0.000193	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CD—prostate cancer	2.78e-05	0.000192	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VAV3—prostate cancer	2.78e-05	0.000191	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFBR2—prostate cancer	2.74e-05	0.000189	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ITPR1—prostate cancer	2.69e-05	0.000186	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIK3CA—prostate cancer	2.68e-05	0.000185	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CB—prostate cancer	2.67e-05	0.000184	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—prostate cancer	2.59e-05	0.000179	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1R—prostate cancer	2.57e-05	0.000178	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCL8—prostate cancer	2.56e-05	0.000177	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—JAK2—prostate cancer	2.55e-05	0.000176	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LPL—prostate cancer	2.47e-05	0.00017	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—IL2—prostate cancer	2.45e-05	0.000169	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDGFRB—prostate cancer	2.45e-05	0.000169	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CSAD—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CBR1—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TST—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADI1—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PSAT1—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GRHL1—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CB—prostate cancer	2.42e-05	0.000167	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ITGB3—prostate cancer	2.38e-05	0.000164	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—prostate cancer	2.37e-05	0.000163	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCL8—prostate cancer	2.33e-05	0.00016	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ERBB3—prostate cancer	2.31e-05	0.000159	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGFR2—prostate cancer	2.31e-05	0.000159	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—UGT2B17—prostate cancer	2.25e-05	0.000155	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GRHPR—prostate cancer	2.25e-05	0.000155	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CKMT2—prostate cancer	2.25e-05	0.000155	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—UGT2B15—prostate cancer	2.25e-05	0.000155	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL2—prostate cancer	2.22e-05	0.000153	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TERT—prostate cancer	2.22e-05	0.000153	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKT1—prostate cancer	2.19e-05	0.000151	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RFK—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PGAM2—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SULT2B1—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AOX1—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAGLU—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MBTPS1—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM3—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HIF1A—prostate cancer	2.12e-05	0.000146	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—prostate cancer	2.07e-05	0.000143	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CAV1—prostate cancer	2.05e-05	0.000141	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KDR—prostate cancer	2.03e-05	0.00014	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AMACR—prostate cancer	2.01e-05	0.000139	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP3A43—prostate cancer	2.01e-05	0.000139	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SRD5A2—prostate cancer	2.01e-05	0.000139	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAT1—prostate cancer	2.01e-05	0.000139	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—DEGS1—prostate cancer	2.01e-05	0.000139	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ESR1—prostate cancer	1.97e-05	0.000136	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BAD—prostate cancer	1.93e-05	0.000133	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.92e-05	0.000132	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APC—prostate cancer	1.87e-05	0.000129	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CG—prostate cancer	1.87e-05	0.000129	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGF—prostate cancer	1.85e-05	0.000127	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS1—prostate cancer	1.85e-05	0.000127	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GSK3B—prostate cancer	1.79e-05	0.000124	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—INS—prostate cancer	1.77e-05	0.000122	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CREBBP—prostate cancer	1.73e-05	0.000119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—prostate cancer	1.71e-05	0.000118	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HPGD—prostate cancer	1.71e-05	0.000118	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.71e-05	0.000118	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—prostate cancer	1.7e-05	0.000117	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAP2K1—prostate cancer	1.65e-05	0.000114	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CD—prostate cancer	1.64e-05	0.000113	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CA—prostate cancer	1.63e-05	0.000112	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—prostate cancer	1.62e-05	0.000112	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—KRAS—prostate cancer	1.61e-05	0.000111	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.61e-05	0.000111	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGF2—prostate cancer	1.57e-05	0.000108	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.56e-05	0.000108	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTAP—prostate cancer	1.56e-05	0.000108	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—prostate cancer	1.55e-05	0.000107	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.52e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.52e-05	0.000105	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—JAK2—prostate cancer	1.51e-05	0.000104	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CA—prostate cancer	1.48e-05	0.000102	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MDM2—prostate cancer	1.47e-05	0.000101	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.45e-05	0.0001	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ACSL4—prostate cancer	1.45e-05	0.0001	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ERBB2—prostate cancer	1.45e-05	0.0001	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CB—prostate cancer	1.43e-05	9.87e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PHGDH—prostate cancer	1.39e-05	9.6e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—UMPS—prostate cancer	1.39e-05	9.6e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ARG2—prostate cancer	1.39e-05	9.6e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL8—prostate cancer	1.37e-05	9.48e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LDHB—prostate cancer	1.37e-05	9.42e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDKN1B—prostate cancer	1.34e-05	9.26e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.34e-05	9.25e-05	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKT1—prostate cancer	1.33e-05	9.16e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CASP3—prostate cancer	1.32e-05	9.07e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL2—prostate cancer	1.31e-05	9.06e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—prostate cancer	1.31e-05	9.02e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PDHA1—prostate cancer	1.29e-05	8.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TCN2—prostate cancer	1.29e-05	8.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—UCP3—prostate cancer	1.29e-05	8.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTA3—prostate cancer	1.29e-05	8.93e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCND1—prostate cancer	1.28e-05	8.83e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CTNNB1—prostate cancer	1.27e-05	8.75e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP9—prostate cancer	1.24e-05	8.58e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDKN1A—prostate cancer	1.24e-05	8.54e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTEN—prostate cancer	1.24e-05	8.53e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.23e-05	8.52e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.23e-05	8.52e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKT1—prostate cancer	1.21e-05	8.32e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.18e-05	8.17e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTA4—prostate cancer	1.18e-05	8.17e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EP300—prostate cancer	1.18e-05	8.13e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTA2—prostate cancer	1.15e-05	7.96e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SRC—prostate cancer	1.15e-05	7.91e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCG5—prostate cancer	1.14e-05	7.86e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.14e-05	7.86e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—prostate cancer	1.12e-05	7.7e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTA1—prostate cancer	1.11e-05	7.68e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—STAT3—prostate cancer	1.11e-05	7.62e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTO1—prostate cancer	1.1e-05	7.59e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAT2—prostate cancer	1.1e-05	7.59e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.1e-05	7.59e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLCB2—prostate cancer	1.06e-05	7.28e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LRP2—prostate cancer	1.06e-05	7.28e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.06e-05	7.28e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—P4HB—prostate cancer	1.03e-05	7.14e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MYC—prostate cancer	1.03e-05	7.08e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—prostate cancer	1.02e-05	7.07e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.01e-05	6.94e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—prostate cancer	1e-05	6.93e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SULT2A1—prostate cancer	9.81e-06	6.77e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MED12—prostate cancer	9.65e-06	6.66e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GNG5—prostate cancer	9.58e-06	6.6e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KRAS—prostate cancer	9.49e-06	6.55e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NCOA3—prostate cancer	9.22e-06	6.36e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HPGDS—prostate cancer	8.8e-06	6.07e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2C19—prostate cancer	8.74e-06	6.03e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	8.72e-06	6.01e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ACHE—prostate cancer	8.53e-06	5.89e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTT1—prostate cancer	8.53e-06	5.89e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2A6—prostate cancer	8.44e-06	5.82e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—prostate cancer	8.44e-06	5.82e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKR1C3—prostate cancer	8.21e-06	5.66e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PRKACB—prostate cancer	8.16e-06	5.63e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP17A1—prostate cancer	8.08e-06	5.57e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—prostate cancer	7.72e-06	5.33e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NCOA2—prostate cancer	7.7e-06	5.31e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC5A5—prostate cancer	7.34e-06	5.07e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2E1—prostate cancer	7.17e-06	4.95e-05	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKT1—prostate cancer	7.12e-06	4.91e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NQO1—prostate cancer	7.09e-06	4.89e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TH—prostate cancer	6.99e-06	4.82e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1B1—prostate cancer	6.8e-06	4.69e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GGT1—prostate cancer	6.59e-06	4.54e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NCOA1—prostate cancer	6.49e-06	4.47e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP19A1—prostate cancer	6.39e-06	4.41e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RXRA—prostate cancer	6.17e-06	4.26e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—COMT—prostate cancer	5.94e-06	4.1e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTP1—prostate cancer	5.92e-06	4.08e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ITPR1—prostate cancer	5.82e-06	4.02e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TYMS—prostate cancer	5.5e-06	3.79e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM1—prostate cancer	5.44e-06	3.75e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPL—prostate cancer	5.34e-06	3.68e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A1—prostate cancer	5.15e-06	3.55e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ERCC2—prostate cancer	5.11e-06	3.53e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—prostate cancer	4.8e-06	3.31e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARA—prostate cancer	4.71e-06	3.25e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CAV1—prostate cancer	4.43e-06	3.06e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.04e-06	2.78e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—INS—prostate cancer	3.82e-06	2.64e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CREBBP—prostate cancer	3.74e-06	2.58e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CD—prostate cancer	3.55e-06	2.45e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—prostate cancer	3.35e-06	2.31e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.09e-06	2.13e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—prostate cancer	3.06e-06	2.11e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTEN—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—EP300—prostate cancer	2.55e-06	1.76e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.89e-06	1.3e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKT1—prostate cancer	1.54e-06	1.06e-05	CbGpPWpGaD
